Industrial Subsidies & PLI
Weekly Roundup
Weekly Brief — Industrial Subsidies & PLI
Industrial Subsidies & PLI Roundup: Government Rejects Bulk Drug Extensions; Launches ₹10,000 Cr Biopharma SHAKTI
This report covers industrial subsidies, PLI schemes, and manufacturing incentives from March 09, 2026, to March 16, 2026. Brought to you by policyindex.ai, this intelligence highlights a strategic pivot toward biopharmaceuticals and a hardening stance on performance-linked timelines.
Key Statistics
| ₹9,207 Crore | 56,800 MT/Annum | ₹10,000 Crore |
|---|---|---|
| Realized Investment in Food Processing PLI (as of Dec 2025) | Installed Domestic Capacity for Bulk Drugs/APIs | Outlay for New 'Biopharma SHAKTI' Scheme |
Weekly Executive Summary
- PLI Extension Denial: The Department of Pharmaceuticals officially rejected requests to extend the tenure of the PLI Scheme for Bulk Drugs, citing a policy to avoid rewarding "non-performers."
- Biopharma SHAKTI Launch: A new ₹10,000 crore initiative was unveiled to establish India as a global hub for biologics and biosimilars, shifting focus from traditional chemicals to high-tech biomanufacturing.
- Strategic Industrial Expansion: Foundation laid for a ₹600-700 crore MNC pharmaceutical facilit…
Download Full Intelligence Brief (PDF)
Sign in to your PolicyIndex account to download the complete executive-ready PDF report including all policy exhibits, data tables, and strategic recommendations.
Log In to Download PDF Brief →